Seres Therapeutics, Inc.

Historical 13F Holders

Symbol
MCRB
CUSIP
81750R102
All holders as of
Q1 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 81750R102 since 12/18/2024, largest first.

Filer % of Class Filed
FMR LLC 13G/A
12.8% 2/12/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q1 65 61.4 M $43.0 M
2024 Q4 76 63.1 M $52.5 M
2024 Q3 85 63.5 M $60.1 M
2024 Q2 100 69.3 M $50.2 M
2024 Q1 107 86.8 M $67.6 M
2023 Q4 116 90.9 M $128 M
2023 Q3 151 109 M $260 M
2023 Q2 152 112 M $538 M
2023 Q1 135 105 M $596 M
2022 Q4 137 110 M $614 M
2022 Q3 129 116 M $743 M
2022 Q2 132 90.9 M $313 M
2022 Q1 144 75.5 M $537 M
2021 Q4 171 78.1 M $650 M
2021 Q3 151 79.6 M $555 M
2021 Q2 169 86.4 M $1.93 B
2021 Q1 173 90.0 M $1.85 B
2020 Q4 168 86.8 M $2.12 B
2020 Q3 136 86.1 M $2.43 B
2020 Q2 105 72.0 M $342 M
2020 Q1 82 76.3 M $272 M
2019 Q4 84 66.7 M $230 M
2019 Q3 84 64.3 M $258 M
2019 Q2 105 62.1 M $200 M
2019 Q1 87 33.8 M $232 M
2018 Q4 74 31.9 M $144 M
2018 Q3 78 32.1 M $244 M
2018 Q2 82 32.0 M $275 M
2018 Q1 84 32.5 M $239 M
2017 Q4 88 32.1 M $326 M
2017 Q3 87 30.8 M $494 M
2017 Q2 77 30.2 M $341 M
2017 Q1 85 30.6 M $344 M
2016 Q4 95 31.2 M $309 M
2016 Q3 102 31.2 M $383 M
2016 Q2 96 31.5 M $916 M
2016 Q1 81 30.9 M $822 M
2015 Q4 76 29.3 M $1.03 B
2015 Q3 62 13.8 M $409 M
2015 Q2 45 11.4 M $471 M